RecruitingNCT04642352

Office-Based Superior Laryngeal Nerve Block for Treatment of Neurogenic Cough

Office-Based Superior Laryngeal Nerve (SLN) Block for Treatment of Neurogenic Cough

Sponsor

University of Alabama at Birmingham

Enrollment

50 participants

Start Date

Jan 3, 2022

Study Type

OBSERVATIONAL

Conditions

Cough

Summary

The purpose of this study is to evaluate if office-based injection of a local anesthetic/steroid combination at the area of one superior laryngeal nerve can decrease cough frequency and alleviate symptoms of chronic cough in patients with neurogenic cough.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called superior laryngeal nerve block for people with cough. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGsuperior laryngeal nerve block

A unilateral injection of 2 cc of a 1:1 mixture of 0.25% bupivacaine and Kenalog-40 via a 27 gauge needle to the thyrohyoid space (front of neck, just above larynx/voice box) via a 27 gauge needle to the thyrohyoid space (front of neck, just above larynx/voice box) on the side which exhibited most discomfort/tenderness/cough on palpation. If neither side was uncomfortable, the right side will be used.